Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin) - Summary - MDSpire

Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)

  • By

  • Emma Guttman-Yassky

  • Alan D. Irvine

  • Melinda Gooderham

  • Stephan Weidinger

  • Lynda Spelman

  • Jonathan I. Silverberg

  • Heidi Crane

  • Hany ElMaraghy

  • Louise DeLuca-Carter

  • Maria Lucia Buziqui Piruzeli

  • Georgia Martimianaki

  • Evangeline Pierce

  • Helena Agell

  • Diamant Thaçi

  • June 19, 2026

  • 0 min

Share

Objective:

To evaluate the long-term efficacy and safety of lebrikizumab in patients with moderate-to-severe atopic dermatitis (AD) over a three-year period, building on previous findings.

Approach:
    Key Findings:
    • Lebrikizumab treatment resulted in durable improvement in signs and symptoms of moderate-to-severe AD through 3 years.
    • The safety profile of lebrikizumab remained consistent with previously reported data.
    Interpretation:

    Limitations:
    • The study primarily focused on participants who achieved a response at week 16, which may not represent the entire patient population.
    Conclusion:

    Lebrikizumab shows potential for long-term efficacy and safety in patients with moderate-to-severe AD based on the study results.

Original Source(s)

Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)

  • by Emma Guttman-Yassky, Alan D. Irvine, Melinda Gooderham, Stephan Weidinger, Lynda Spelman, Jonathan I. Silverberg, Heidi Crane, Hany ElMaraghy, Louise DeLuca-Carter, Maria Lucia Buziqui Piruzeli, Georgia Martimianaki, Evangeline Pierce, Helena Agell, Diamant Thaçi

  • June 19, 2026

Related Content

Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study from Italy Emphasizing Head and Neck Areas

Editorial: Exploring Cutaneous Drug-Related and Drug-Associated Adverse events: from Clinical Insights to Therapeutic Management

Summary of Research: Immunogenicity of Dupilumab in Adult and Pediatric Patients with Atopic Dermatitis